Paola Stefanía Calles Monar

Mrs. Paola Stefanía Calles Monar

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Archivos de la Sociedad Española de Oftalmología
Verified
Journal Article
Closed access
PMPaola Stefanía Calles Monar
Paola Stefanía Calles Monar
AMA. Juárez Martín
A. Juárez Martín

2 February 2023 in Archivos de la Sociedad Española de Oftalmología (English Edition)
Verified
Journal Article
Closed access
PMPaola Stefanía Calles Monar
Paola Stefanía Calles Monar
VFV.E. Marqués Fernández
V.E. Marqués Fernández
HSHortensia Sanchez-Tocino
Hortensia Sanchez-Tocino
AGA. Galindo-Ferreiro
A. Galindo-Ferreiro

29 April 2022 in Drugs & Aging
Verified
Journal Article
Closed access
PDF file
PMPaola Stefanía Calles Monar
Paola Stefanía Calles Monar
MSMaría R. Sanabria
María R. Sanabria
AAAna M. Alonso-Tarancon
Ana M. Alonso-Tarancon
Rosa M. Coco-MartinRosa M. Coco-Martin
Rosa M. Coco-Martin
AMAgustín Mayo-Iscar
Agustín Mayo-Iscar

20 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMaría R. Sanabria
María R. Sanabria
PMPaola Stefanía Calles Monar
Paola Stefanía Calles Monar
AAAna M. Alonso-Tarancón
Ana M. Alonso-Tarancón
Rosa M. Coco-MartinRosa M. Coco-Martin
Rosa M. Coco-Martin
MAMayo-Iscar Agustín
Mayo-Iscar Agustín
Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries. Intravitreal injections of antiangiogenic agents (anti-VEGF) can stop vision loss in the neovascular form of the disease (nAMD). The aim of this study was to assess the general health-related quality of life (HRQoL) in a cohort of patients with nAMD treated with intravitreal anti-VEGF injections and to detesrmine to what extent their HRQoL was affected by COVID-19. This was an observational, analytical, and longitudinal study performed with a two-wave panel survey. Clinical outcomes, HRQoL, and tangible support were evaluated. In the final survey, changes in living conditions and medical visits due to the COVID-19 pandemic were also examined. Of the 102 patients initially interviewed in the before-COVID survey, 24 were lost after 30 months of follow-up. In the initial assessment, the mean health index was 0.73 ± 0.2. The EQ VAS score worsened at the final survey (p = 0.048). Patients needing treatment in both eyes (p = 0.007) and with lower levels of bilateral visual acuity (p = 0.018) reported an increase in social support at the final survey. In conclusion, patients perceived a worsening in HRQoL after confinement. However, patients enjoyed good social support that improved in the after-COVID survey.

12 January 2023 in Archivos de la Sociedad Española de Oftalmología
Verified
Journal Article
Closed access
PMPaola Stefanía Calles Monar
Paola Stefanía Calles Monar
VFV.E. Marqués Fernández
V.E. Marqués Fernández
HSHortensia Sanchez-Tocino
Hortensia Sanchez-Tocino
AGA. Galindo-Ferreiro
A. Galindo-Ferreiro